Market Overview

Benzinga's Top #PreMarket Gainers

Related ALNY
Why Investors Should Take Another Look At Alnylam Pharmaceuticals
Data Monitoring Committee Determines Alnylam's ENDEAVOUR Trial May Continue
Related MRK
Technical Alert: Merck Higher After Q3 Report
6 Big Pharma Companies Left To Report September Quarterly Figures
Merck's Keytruda Receives First-Line Nod From FDA In Lung Cancer: What Does It Mean? (Seeking Alpha)

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares jumped 35.93% to $90.00 in pre-market trading after the company reported that it has acquired investigational RNAi Therapeutic assets from Merck (NYSE: MRK). Genzyme and Alnylam expanded their collaboration on rare genetic diseases.

Beam (NYSE: BEAM) shares gained 25.93% to $84.35 in the pre-market after the company agreed to be acquired by Suntory Holdings for $83.50 per share in cash.

NII Holdings (NASDAQ: NIHD) surged 20.81% to $2.70 in the pre-market session after the company and Telefonica signed agreements to provide wholesale voice and data services to Nextel in Brazil and Mexico.

Clovis Oncology (NASDAQ: CLVS) soared 6.99% to $79.15 in the pre-market trading after the company announced 2014 objectives and financial outlook.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers


Related Articles (ALNY + BEAM)

View Comments and Join the Discussion!